• Geron published a real-world outcomes report on imetelstat in heavily pretreated lower-risk MDS patients treated at Moffitt Cancer Center.
• RBC transfusion independence longer than 8 weeks reached 37.5% (15 of 40); median response duration was 185 days; 7 responses remained ongoing.
• Exploratory modeling flagged baseline platelet count, ASXL1 mutation status, and IPSS-R at diagnosis as key response predictors.
• Grade 3/4 neutropenia ran 35% after cycle 1; 22.5% after cycle 2; no febrile neutropenia reported.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Geron Corporation published the original content used to generate this news brief on June 12, 2026, and is solely responsible for the information contained therein.